Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Platelet-activating factor (PAF) is a potent endogenous proinflammatory mediator implicated in the pathogenesis of septic shock. A double-blind randomized placebo-controlled trial of an intravenous PAF receptor antagonist (lexipafant) was conducted with 131 adult Thai patients with suspected severe sepsis (66 of whom had positive blood cultures). Detailed serial clinical, biochemical, and cytokine measurements were performed. Lexipafant treatment was well tolerated. The 28-day mortality in the lexipafant group (61.4%) was similar to that in the placebo group (62.6%). There was also no evidence that lexipafant affected clinical or biochemical measures of disease severity or the profile of sequentially measured plasma cytokine levels. PAF may not have an important role in the pathogenesis of severe sepsis.

Original publication

DOI

10.1128/aac.44.3.693-696.2000

Type

Journal article

Journal

Antimicrob Agents Chemother

Publication Date

03/2000

Volume

44

Pages

693 - 696

Keywords

Bacterial Infections, Cytokines, Double-Blind Method, Humans, Imidazoles, Lactates, Leucine, Platelet Membrane Glycoproteins, Receptors, Cell Surface, Receptors, G-Protein-Coupled, Sepsis